Compare Prologis Inc (PLD) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Prologis Inc vs TransMedics Group Inc — how do they compare? Prologis Inc trades at $136.97 (market cap $131.60B), while TransMedics Group Inc trades at $85.89 (market cap $3.06B). The key difference: Prologis Inc is far larger — about 43× TransMedics Group Inc's market cap, and Prologis Inc pays a 3.09% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| PLD | TMDX | |
|---|---|---|
Market Cap | $131.60B | $3.06B |
Sector | Real Estate | Technology |
52-Week High | $149.96 | $150.42 |
52-Week Low | $110.98 | $61.99 |
Enterprise Value | $166.34B | $3.46B |
Dividend Yield | 3.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Prologis (PLD) trades at $138.49, up 0.84% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.13 exceeding the $0.747 estimate. Revenue grew to $8.79 billion in 2025, though net income margin dipped to 37.86%. The stock faces headwinds from a high P/E of 30.84 and rising debt-to-asset ratio, now at 37.2% for 2025. Recent news highlights institutional buying interest amid market volatility.
The outlook for PLD is mixed, with analyst consensus bullish (59.52% buy ratings) and a $160.13 price target suggesting 15.6% upside. Key opportunities include sustained revenue growth and dividend stability, but risks involve elevated valuation, debt levels, and macroeconomic sensitivity. The stock's performance hinges on Q3 2026 earnings and the integration of the SEGRO acquisition.
TransMedics Group (TMDX) trades at $88.27, down 1.9% on the day, with a bullish technical signal from moving averages but mixed earnings results. The company reported strong revenue growth to $605.49M in 2025, with a net income margin of 22.69%, though profitability is expected to moderate in 2026. Recent news highlights ongoing legal investigations into fiduciary duties alongside positive coverage of growth initiatives in kidney transplantation and European expansion.
The stock presents a growth opportunity with analyst consensus pointing to a $99.57 price target, but risks include margin pressure from heavy investments and legal uncertainties. Earnings misses in recent quarters and a projected decline in net income for 2026 warrant caution, though institutional interest remains with a bullish rating from 69% of analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Prologis Inc
Prologis was formed by the June 2011 merger of AMB Property and Prologis Trust. The company develops, acquires, and operates around 1 billion square feet of high-quality industrial and logistics facilities across the globe. The company also has a strategic capital business segment that has around $70 billion of third-party AUM. The company is organized into four global divisions (Americas, Europe, Asia, and other Americas) and operates as a real estate investment trust.
Read more on PLD →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
